Dusan Stefoski to Follow-Up Studies
This is a "connection" page, showing publications Dusan Stefoski has written about Follow-Up Studies.
Connection Strength
0.116
-
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730.
Score: 0.038
-
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26; 16:117.
Score: 0.024
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014 May; 13(5):472-81.
Score: 0.020
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75.
Score: 0.019
-
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009 Mar; 8(3):244-53.
Score: 0.014